Ryan Haumschild, PharmD, MS, MBA

March 01, 2022

A panel of experts share closing thoughts and advice for the management and uptake of HIV PrEP therapy.

March 01, 2022

Carl Schmid shares insight on the use of advocacy groups to help patients overcome barriers to access for HIV PrEP therapy.

February 22, 2022

Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid explore organizational opportunities to improve access to HIV PrEP therapy and population health management strategies to improve PrEP uptake.

February 22, 2022

Carl Schmid discusses how the COVID-19 pandemic has amplified health care disparities and accessing HIV PrEP, and Frank J. Palella, MD, comments on the role of telehealth in improving access to PrEP.

February 16, 2022

February 15, 2022

Ryan Bitton, PharmD, MBA, provides a payer perspective on the importance of creating future health policies for HIV PrEP agents using real-world evidence and considering the total cost of care for patients.

February 15, 2022

Ryan Bitton, PharmD, MBA; Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid comment on challenges in the implementation of USPSTF guidelines for HIV PrEP as well as existing unknowns with the guidance.

February 08, 2022

Frank J. Palella, MD, shares a provider perspective for steps to take in accordance with USPSTF guidelines for HIV PrEP to get patients appropriate medications, and Ryan Bitton, PharmD, MBA, shares a provider prospective on supporting expedited prior authorizations.

February 08, 2022

Sean E. Bland, JD, provides insight for when a health plan or issuer may use reasonable medical-management techniques, in accordance with USPSTF guidelines for HIV PrEP, and Ryan Bitton, PharmD, MBA, shares a payer perspective on utilization-management policies regarding PrEP.

February 07, 2022

Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.